Discover if this is a suitable investor for your startup. If they are we'll make a warm introduction for free. Otherwise, we'll connect you with matching investors.
Blue Goose Capital is a venture capital firm founded in 2024, based in the United States. The firm focuses exclusively on the biotechnology sector, aiming to connect global talent with US-based funding and leadership. This unique approach requires offshore portfolio companies to relocate their senior management to the United States, enhancing their potential for success in the biotech industry.
Currently, Blue Goose Capital operates two funds: Blue Goose Capital 1 (BG1), which targets seed stage investments, and Blue Goose Capital 2 (BG2), which focuses on Series A funding rounds. The firm has established a strong presence in the biotech landscape, leveraging its extensive network within the industry to support its portfolio companies.
As a new entrant in the venture capital space, Blue Goose Capital is committed to fostering innovation in biopharma and medical devices. The firm’s strategy is designed to ensure that its portfolio companies are well-positioned to thrive in the competitive biotech market.
Blue Goose Capital primarily invests in biotechnology companies, with a strong emphasis on Series A funding rounds through its second fund, Blue Goose Capital 2 (BG2). The firm also engages in seed stage investments via its first fund, Blue Goose Capital 1 (BG1). This dual-fund structure allows Blue Goose Capital to support startups at various stages of development, from early seed funding to more advanced Series A rounds.
The firm’s investment strategy is centered on biopharma and medical devices, targeting innovative solutions that address significant healthcare challenges. Blue Goose Capital seeks to partner with companies that demonstrate strong growth potential and are committed to relocating their senior management to the US, thereby enhancing their operational capabilities and market access.
Geographically, Blue Goose Capital focuses on the United States while also considering talent and early-stage companies from Spain. This international perspective allows the firm to tap into a diverse pool of innovative biotech solutions.
Blue Goose Capital has a focused portfolio that includes notable companies in the biotechnology sector. Key portfolio companies include:
These companies reflect Blue Goose Capital's commitment to supporting innovative solutions in the healthcare sector, particularly in biopharma and medical devices.
Doug Zingale, Managing Partner — Doug Zingale co-founded Blue Goose Capital and oversees both BG1 and BG2. He is an MIT alumnus and has extensive experience in the biotech sector, having worked with Biogen and Vertex on major financial and strategic transactions since the 1980s. Zingale also served as the General Manager for Strategic Partnerships at Microsoft and has been a business advisor at Inspirna Pharmaceuticals and Mythic Therapeutics. He is a co-founder of Ignite Technology Ventures and has been involved in several MIT spin-outs. Additionally, he lectures on venture capital at Esade in Spain and serves as a startup advisor at Harvard Business School and Swissnex.
To pitch Blue Goose Capital, founders should seek a warm introduction through the firm's network. A well-prepared pitch deck should include details about the business model, market opportunity, and growth strategy. While specific response time expectations are not disclosed, founders should be prepared for a thorough evaluation process.
In March 2024, Blue Goose Capital announced the successful completion of a $40 million Series A funding round for Therini Bio, Inc., a company focused on Alzheimer's disease. This funding round included co-investors such as SV Health, Dreavent, Merck, Eli Lilly, and Sanofi.
Blue Goose Capital continues to build its portfolio with a focus on innovative biotechnology companies, particularly those that align with its investment thesis of relocating senior management to the US.
What are Blue Goose Capital's investment criteria?
Blue Goose Capital focuses on biotechnology companies, specifically targeting seed to Series B stages. The firm emphasizes investments in biopharma and medical devices, seeking startups that demonstrate strong growth potential and innovative solutions.
How can I pitch to Blue Goose Capital?
Founders interested in pitching to Blue Goose Capital should prepare a detailed presentation that outlines their business model, market opportunity, and growth strategy. The firm prefers to receive pitches through warm introductions from their network.
What makes Blue Goose Capital different from other VC firms?
Blue Goose Capital's unique approach requires offshore portfolio companies to relocate their senior management to the United States. This strategy aims to enhance the operational capabilities of these companies and improve their chances of success in the US market.
What is the geographic focus of Blue Goose Capital?
The firm primarily invests in the United States but also considers early-stage companies and talent from Spain. This dual focus allows Blue Goose Capital to leverage global talent while anchoring leadership in the US.
What is the typical check size for investments?
While specific check sizes are not disclosed, Blue Goose Capital targets seed stage investments through BG1 and Series A funding through BG2. The firm aims to provide sufficient capital to support the growth of its portfolio companies.
What kind of support does Blue Goose Capital provide to its portfolio companies?
Blue Goose Capital adds value to its portfolio companies by leveraging its extensive network in the biotech and pharmaceutical industries. The firm provides strategic guidance and support to help companies navigate the complexities of the biotech landscape.
All trademarks, logos and brand names are the property of their respective owners. All company, product and service names used in this website are for identification purposes only. Use of these names, trademarks, and brands does not imply endorsement.